Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $14.00

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been given an average rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $14.00.

Several research analysts have commented on NRSN shares. Zacks Research upgraded shares of NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research report on Friday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Wednesday, October 8th. Finally, Noble Financial upgraded shares of NeuroSense Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th.

NeuroSense Therapeutics Price Performance

Shares of NRSN opened at $1.16 on Friday. NeuroSense Therapeutics has a one year low of $0.80 and a one year high of $2.60. The company has a market cap of $15.86 million, a P/E ratio of -2.15 and a beta of 1.61. The firm has a 50 day simple moving average of $1.19 and a two-hundred day simple moving average of $1.44.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,689 shares of the company’s stock, valued at approximately $54,000. Jane Street Group LLC owned approximately 0.21% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.